Brought to you by 
Celgene, Sutro sign antibody deal; later expanded
27 Oct 2021
Executive Summary
Sutro Biopharma Inc. (large molecule therapeutics) will design and develop optimized antibody drug conjugates (ADCs) and bispecific antibodies (BSAs) for two of Celgene Corp.’s undisclosed targets.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Synthesis Technologies, Production Processes
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Includes M&A Option
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Celgene, Sutro sign antibody deal; later expanded
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice